Lannett announced that its subsidiary Silarx has received approval from the Food and Drug Administration (FDA) for Aripiprazole Oral Solution, the generic version of Otsuka’s Abilify.
Abilify is an atypical antipsychotic indicated for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder, adjunctive treatment of major depressive disorder, irritability associated with autistic disorder, and treatment of Tourette’s disorder. Its mechanism of action in schizophrenia or bipolar mania, is unknown. However, the efficacy of aripiprazole could be mediated through a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors.
RELATED: Some Abilify Formulations to Discontinue in 2015
Aripiprazole Oral Solution is available as a 1mg/mL strength.
For more information call (215) 333-9000 or visit Lannett.com.